Compare Hecla Mining Company Common Stock (HL) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hecla Mining Company Common Stock vs Natera Inc. Common Stock — how do they compare? Hecla Mining Company Common Stock trades at $15.06 (market cap $10.87B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.2× Hecla Mining Company Common Stock's market cap, and Hecla Mining Company Common Stock pays a 0.09% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hecla Mining Company Common Stock for 3 Days and Natera Inc. Common Stock for 0 Days on average.
| HL | NTRA | |
|---|---|---|
Market Cap | $10.87B | $57.03B |
Volume | 31,516,848 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $31.81 | $425.64 |
52-Week Low | $11.97 | $179.42 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $10.40B | $56.18B |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hecla Mining (HL) trades at $16.18, down 3.92% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 51.68% gross margin and 19.15% net income margin, but recent quarterly earnings missed expectations. Positive news highlights a debt-free balance sheet and organic growth targeting over 20 million silver ounces, while institutional activity includes new investments from Bank of America and AlphaGrep.
The outlook is mixed: analyst consensus is a Buy with a $23.44 price target, implying 45% upside, but technical indicators signal near-term pressure. Key risks include silver price volatility and execution of growth projects. The stock presents a value opportunity for long-term investors if operational targets are met.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hecla Mining Company Common Stock
Hecla Mining is a precious metals producer focused on silver and gold. It operates mines in the United States and Canada.
Read more on HL →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
